EPO and sleep apnea syndrome: Six-month administration of acetazolamide, a carbonic anhydrase inhibitor, stimulated respiratory response and rectify hypoxemia, and thus reduced Hct, EPO and pulmonary vascular resistance and even improved sleep-related breathing disorders (59, 60).